SpyGlass Pharma, Inc.
SGPDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
8dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
SGP Earnings Report
EPS Est: $-0.48 | FQ end 2026-06
Bimatoprost Implant System
Cataract
Timolol Maleate Ophthalmic Solution, 0.5%
Cataract
Bimatoprost Implant System (High Dose)
Cataract
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Bimatoprost Implant System | Phase 3 | Cataract | - | - |
Timolol Maleate Ophthalmic Solution, 0.5% | Phase 3 | Cataract | - | - |
Bimatoprost Implant System (High Dose) | Phase 2 | Cataract | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in SpyGlass Pharma, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in SpyGlass Pharma, Inc.'s (SGP) pipeline across Phase 3, Phase 2. Its lead program is Bimatoprost Implant System (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is SpyGlass Pharma, Inc.'s next FDA catalyst?→
SpyGlass Pharma, Inc.'s (SGP) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SGP biotech catalysts?→
Add SGP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow SpyGlass Pharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.